Bosnalijek

Bosnalijek is a pharmaceutical company based in Sarajevo, Bosnia and Herzegovina. Established in 1951 in Sarajevo, then part of the Federal People's Republic of Yugoslavia, the company developed into one of the country's principal medicine manufacturers and is described as Bosnia and Herzegovina's largest pharmaceutical company. Its activities cover the manufacture and marketing of prescription medicines, over-the-counter products, and other health-related pharmaceutical offerings. The company serves the domestic Bosnian market while also exporting across Southeast Europe and other international markets; available reference material places its commercial presence in more than 20 markets. A major stage in Bosnalijek's industrial development came in 2005, when the International Finance Corporation extended a €7.5 million loan connected with construction of a new production and distribution center. The planned facility represented an overall investment of approximately €18.5 million and was intended to strengthen manufacturing and logistics capacity. This investment formed part of the company's longer-term effort to operate as a modern regional pharmaceutical producer rather than solely as a domestic supplier. Bosnalijek marked its 65th anniversary in August 2016. Later that year, in October, the Government of the Federation of Bosnia and Herzegovina auctioned its remaining shares in the company, completing a further step in the reduction of direct state ownership. The available reference material does not identify a single private parent company or controlling group following that transaction. By 2019, foreign markets were reported to account for approximately 76 percent of Bosnalijek's total revenue, illustrating the importance of exports to its business model. Reference material also reports annual revenue of around €80 million in 2018; this figure is time-specific and should not be treated as a current financial measure. Bosnalijek's positioning is therefore that of a nationally important, export-oriented pharmaceutical manufacturer with a broad regional footprint. Detailed information about individual branded medicines, current executives, ownership percentages, and present-day financial performance is not established by the supplied sources.

Bosnalijek was established in 1951 in Sarajevo, at the time within the Federal People's Republic of Yugoslavia. Its historical role has been tied to the development of pharmaceutical manufacturing in Bosnia and Herzegovina, where it became a major domestic producer of medicines and a prominent industrial company. The company's later development included investment in production and distribution infrastructure. In 2005, the International Finance Corporation provided Bosnalijek with a €7.5 million loan for a project whose total planned value was approximately €18.5 million. The project involved construction of a production and distribution center, supporting the company's manufacturing base and its ability to handle pharmaceutical logistics. The supplied reference does not provide the facility's completion date or a detailed account of the product technologies installed there. Bosnalijek continued operating as a Bosnian pharmaceutical company with an expanding international presence. By 2019, it was represented in more than 20 markets, and foreign-market revenue reportedly made up 76 percent of total revenue. This export share indicates that international sales had become central to the company rather than merely supplementary to its domestic business. Its main geographic emphasis is described as Southeast Europe, although the company is also reported to have a presence beyond that region. In August 2016, Bosnalijek commemorated its 65th anniversary. Two months later, in October 2016, the Government of the Federation of Bosnia and Herzegovina sold its remaining shares through an auction. This marked an important ownership milestone, but the supplied material does not identify the successful buyers, the resulting ownership structure, or any subsequent parent company. The available reference describes Bosnalijek as Bosnia and Herzegovina's largest pharmaceutical company and reports annual revenue of approximately €80 million for 2018. Because the figure is tied to a specific year and no newer financial data is supplied, it is best understood as historical context rather than a current valuation or performance indicator. Publicly available details in the supplied materials are limited regarding specific product brands, research programs, leadership, regulatory events, and recent corporate developments. Accordingly, the company's documented profile is strongest on its founding, infrastructure investment, export orientation, anniversary, and partial privatization history.

• 2019

  International markets became central to revenue

  [1]Bosnalijeken.wikipedia.org

  Reference material reported that Bosnalijek was present in more than 20 markets and that foreign markets generated approximately 76 percent of total revenue.

• 2016

  65th anniversary and state-share auction

  [1]Bosnalijeken.wikipedia.org

  Bosnalijek celebrated its 65th anniversary in August. In October, the Government of the Federation of Bosnia and Herzegovina auctioned its remaining shares in the company.

• 2005

  International Finance Corporation financing

  [1]Bosnalijeken.wikipedia.org

  The International Finance Corporation provided a €7.5 million loan supporting construction of a production and distribution center with a reported total project value of approximately €18.5 million.

• 1951

  Company established in Sarajevo

  [1]Bosnalijeken.wikipedia.org

  Bosnalijek was founded in Sarajevo in the Federal People's Republic of Yugoslavia, in the territory now constituting Bosnia and Herzegovina.

Nationally significant and export-oriented pharmaceutical manufacturer serving Bosnia and Herzegovina, Southeast Europe, and additional international markets.

• Pharmaceuticals

  Prescription medicines

  Prescription medicines form part of Bosnalijek's core pharmaceutical manufacturing and commercial portfolio. The supplied sources establish the category but do not provide a reliable list of individual products, therapeutic areas, active ingredients, or current brand names.

• Consumer healthcare

  Over-the-counter medicines

  Bosnalijek also produces and markets over-the-counter pharmaceutical products intended for use without a prescription. Available reference material does not specify the individual product families or markets in which each product is sold.

• Healthcare products

  Pharmaceutical health products

  The company is associated broadly with health-related pharmaceutical offerings in addition to prescription medicines. The supplied sources do not support a more specific description of supplements, medical devices, or other product classes, so the category is stated conservatively.

1. 1Bosnalijeken.wikipedia.org
2. 2Bosnalijek official websitebosnalijek.ba